News
Bachmann’s pioneering DFMO research leads to FDA-approved lifesaving cancer drug
The U.S. Food and Drug Administration has approved a drug to treat neuroblastoma, an often-fatal pediatric cancer, based on pioneering research by College of Human Medicine professor André Bachmann.
The FDA approved a tablet form of a drug called difluoromethylornithine, or DFMO (synonym eflornithine), developed in 1978 and later used to treat West African sleeping sickness. The agency’s approval will allow doctors to use oral DFMO to reduce the rate of relapses in patients who have previously undergone standard therapy for neuroblastoma.
MSU researchers find early, promising glioblastoma treatment
A team of Michigan State University scientists has unveiled a potential game-changer in the fight against glioblastoma, the most common and currently incurable form of brain cancer.
Their weapon of choice? A drug-like compound named Ogremorphin, or OGM. In laboratory experiments, OGM showed a remarkable ability to kill glioblastoma cells while leaving normal cells unharmed.
A Spartan Changing the Way We Fight Cancer
Carolina de Aguiar Ferreira couldn’t do what she does anywhere else.
The assistant professor has the resources at Michigan State University to precisely target cancer cells with diagnostics and therapies using radioisotopes produced by what is designed to be the world's most powerful heavy-ion accelerator.
When considering where to pursue her career, she knew MSU provided the perfect environment.